TheDaoIndex KDAO2011
2 years 7 months ago
“Flares require a trigger!” – Dr. M Kahlenberg on #SLE flares #RNL2024 @rheumnow https://t.co/rqAnAOfJZP
TheDaoIndex KDAO2011
2 years 7 months ago
Is it a lupus flare or a mimic? Fibromyalgia, stress, infection, poor sleep, hypothyroidism, vitamin deficiencies can contribute to pain and fatigue in a patient. – Dr. M Kahlenberg #RNL2024 @rheumnow https://t.co/pLuqyy8gHm
TheDaoIndex KDAO2011
2 years 7 months ago
Lupus has many flavors. If we are better able to sort them, we might be more better at finding effective treatments. @rheumnow #RNL2024 @DrDavidKarp https://t.co/rklqnA8Ur6
TheDaoIndex KDAO2011
2 years 7 months ago
"SLE affects women in the prime of their life, 25% of pts go to the ER, up to 50% will have lupus nephritis; it is a deadly and costly disease.” - @DrDavidKarp on why we would be focusing on identifying preclinical SLE and preventing the disease #RNL2024 @rheumnow https://t.co/SIZ5ZBwu94
TheDaoIndex KDAO2011
2 years 7 months ago
Should we define preclinical SLE as stages rather than using confusing nomenclatures like UCTD, incomplete lupus, etc? - @DrDavidKarp @rheumnow #RNL2024 https://t.co/OjRjdBzJWE
TheDaoIndex KDAO2011
2 years 7 months ago
When should you intervene? We talk about primary and secondary prevention... but what about primordial prevention that targets social determinants of health? - @drdavidkarp #RNL2024 @rheumnow https://t.co/UGAcNFLqZf
TheDaoIndex KDAO2011
2 years 7 months ago
What early biomarkers are specific for SLE? How many will progress to stage 2? Who should we screen? Will patients revert to pre-stage 1? Is progression preventable? @DrDavidKarp on relevant questions we need to ask regarding preclinical stage 1 lupus. #RNL2024 @rheumnow https://t.co/bJPG68WdyE
TheDaoIndex KDAO2011
2 years 7 months ago
Can HCQ prevent SLE? Results of the MONA-LISA study is being analyzed (pts have +ANA and 1-2 SLICC criteria for SLE randomized to PCB or HCQ) - @DrDavidKarp @rheumnow #RNL2024 https://t.co/9yoFXS7wMe
Eric Dein ericdeinmd
2 years 7 months ago
#RNL2024 @RheumNow
@DrDavidKarp
Incomplete lupus is heterogeneous term
"Stage 2" pre-classification stage as ILE/UCTD
Stage 1: non-specific antibodies, dysregulation
2: incomplete features
3: classified, multi-system disease
4: irreversible tissue damage https://t.co/CuLUzSZ24E
Nouf Al hemmadi NoufAhmedAlham2
2 years 7 months ago
@reumacia @RheumNow You are absolutely right. The point was not generally used for psoriasis ( not PsA). I was surprised my self 🤕.
Here is the slide again by Dr. Armstrong , great talk by the way. Let me know if you want the handout. https://t.co/C11Gkn2jho
Nouf Al hemmadi NoufAhmedAlham2
2 years 7 months ago
Appreciative inquiry in rheumatology and how to enhance and improve our clinical notes to frame our encounter in a positive manner.
@BharatKumarMD
#RNL2024
@RheumNow https://t.co/iTXwjUb6tg
Nouf Al hemmadi NoufAhmedAlham2
2 years 7 months ago
Some takeways from JAK inhibitors in dermatology talk by Bruce Strober.
Great talk.
#RNL2024
@RheumNow https://t.co/fuRsSnnsha
Nouf Al hemmadi NoufAhmedAlham2
2 years 7 months ago
Alopecia aerate and JAK
Bruce Strober
#RNL2024
@RheumNow https://t.co/lGig1Vpf5x
Nouf Al hemmadi NoufAhmedAlham2
2 years 7 months ago
Examples from the world of dermatology on JAK inhibitor success stories.
Bruce storber.
#RNL2024
@RheumNow https://t.co/S01lEIqjbR
Nouf Al hemmadi NoufAhmedAlham2
2 years 7 months ago
Dermatology colleagues are using JAKis with success for wide range of dermatological diseases.
Note the beauty of this slide with further elaboration on domain inhibition, cool stuff 🤓
Bruce Strober
#RNL2024
@RheumNow https://t.co/2yHHcOgTC8
